About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

FDA Seeks Advice From Blogger; Google Solves Pharma's Ad Problems

By Jim Edwards | Nov 12, 2009

The FDA sought the advice of John Mack, a blogger with 20,000 monthly readers who runs the Pharma Marketing Blog, on how drug companies should use the web to advertise their products. The agency usually likes to hear from lawyers, drug company executives and academics when it seeks regulatory advice.

The FDA is holding a two-day hearing on whether it should change its drug advertising rules to help pharmaceutical companies use “Web 2.0″ and social media without falling afoul of FDA regulations. The hearings come after the FDA warned 14 drug companies for using Google ads that did not disclose drug side effect warnings; the companies attest that it is virtually impossible to squeeze those warnings into such tiny ads. Google testified at the hearings that it had a solution to that (below).

But the FDA’s selection of Mack as one of the speakers to address its panel has raised eyebrows in the business, if BNET’s email inbox is to be believed. Some point out that a survey Mack relies on in his testimony was simply a SurveyMonkey poll that Mack attached to his blog in order to poll his own readers. — i.e. not a representative sample. (For context, BNET Pharma has at least five times as many readers as Pharma Marketing Blog.)

Mack is clearly presenting himself with tongue firmly in cheek. Among his qualifications he cites two satirical cartoon characters he invented when commenting on regulatory issues:

Creator of “PhRMA Intern” and “FDA Intern” — strange bedfellows or mortal enemies?

Mack has already been cited by Reuters for his efforts.

More significantly, Google showed up to solve the Google ad problem (pictured below). PharmExec noted:

According to Mary Ann Belliveau, Google’s director of health care advertising, the new ads will include both brand name and health care information, as well as a brand URL. To make the ads FDA compliant, each unit will include an abridged warning notice that links to the full risk information. The lead subject line will link to the brand site, so each ad will have two different URLs linking to two different locations.

Neat!

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • GSK and Centocor Abandon Their Pioneering Corporate Drug Blogs

    BNET Pharma - 315 days 16 hours 9 minutes ago

    Two companies who made early runs at corporate blogging — GlaxoSmithKline and Centocor – appear to have let their blogs die. The deaths were noted first by Pharma Marketing blogger John Mack. GSK’s blog was for its weight-loss drug, Alli, and was called AlliConnect. The last post on that blog was on Sept. 3, 2008. BNET has previously noted...

  • Overactive marketing for overactive bladder

    Schwitzer - 229 days 46 minutes ago

    A classic example of disease mongering. That's what blogger John Mack writes on his Pharma Marketing blog - about a slide presentation he found from a drug company exec pushing the drug, Detrol, for overactive bladder. Mack writes: "I remembered being present at the 2002 meeting and how shocked I was that a pharmaceutical VP would...

  • Drug Marketing Strategy 101

    Schwitzer - 73 days 50 minutes ago

    On the Pharma Marketing Blog, John Mack writes about weight loss drug Alli: "Alli is a great case study of what pharmaceutical companies would do if there were fewer or no FDA regulations to contend with - they would enhance the benefits and downplay the side effects

  • Who should Obama pick for FDA Commissioner?

    The Health Care Blog - 346 days 2 hours 16 minutes ago

    By John Mack  It seems like everyone in the Pharma Blogosphere and the press is recommending who president-elect Barack Obama should nominate as the new FDA Commissioner to replace Dr. Andrew von Eschenbach. A few weeks ago, I created the “Who Should Obama Nominate for FDA Commissioner?” online survey to determine who readers of Pharma...

  • How will the FDA regulate drug promotion via blog, podcast, social network, etc.?

    Schwitzer - 213 days 16 hours 59 minutes ago

    John Mack tackles the question on his Pharma Marketing blog.

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
Click Here
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here